Ceranib-2 potentiates cisplatin activity under an experimental in vitro hipec-like model by inducing integrated stress and cell death pathways in ovarian cancer
Abstract
This study aims to investigate whether the addition of Ceranib-2, an acid ceramidase inhibitor, could enhance the cytotoxic efficacy of cisplatin under hyperthermic conditions using an OVCAR-3 ovarian cancer cell model. The combination of cisplatin and ceranib-2, administered at a tolerable hyperthermic temperature of 39 ˚C, significantly decreased cell viability and induced robust programmed cell death compared to monotherapies. Notably, our findings reveal a complex mechanistic interplay: while cisplatin monotherapy primarily relied on ROS-dependent pathways, the combination treatment triggered potent anticancer effects through ceramide-driven ER stress and autophagy, even exhibiting lower ROS levels than cisplatin alone. This suggests a shift toward ROS-independent death mechanisms. Furthermore, we observed a significant 4-fold upregulation of the anti-apoptotic protein Bcl-2 in the combination group. This increase is characterized as a compensatory pro-survival response to intense cellular stress, which was ultimately overwhelmed by the marked activation of caspase-3/7 and mitochondrial depolarization. The integration of in vitro GDH activity measurements and in silico molecular docking analyses suggests that ceranib-2 may interact with glutamate dehydrogenase (GDH), potentially contributing to the observed reduction in GDH activity. The docking results further indicate a possible interaction with the NAD⁺-binding domain and C-terminal α-helix, supporting a putative allosteric binding mode that warrants further experimental validation. Additionally, the combination treatment significantly impaired the colony-forming ability and spread of tumor cells. These results demonstrate that the cisplatin and ceranib-2 combination elicit a synergistic effect by utilizing complementary pathways to overcome chemoresistance. Consequently, this study provides valuable insights and experimental evidence for future optimization of HIPEC protocols by targeting ceramide metabolism and ER stress signaling to improve therapeutic outcomes in ovarian cancer.
Related
- Ascorbic Acid Potentiates Cisplatin-Induced Antitumor Activity in HeLa Cervical Cancer Cells: Oxidative Stress, Mitochondrial Dysfunction, Apoptosis, and 3D Spheroid Responses
- Integrated toxicogenomic and single-nucleus transcriptomic analyses prioritize SDHB and NDUFAB1 in mitochondrial respiration-associated remodeling during cisplatin-induced acute kidney injury
- Luteolin potentiates antibiotic activity against multidrug-resistant Pseudomonas aeruginosa and modulates efflux-associated resistance and biofilm-associated phenotypes
- A novel stilbene derivative targets RAD51 activity and sensitizes DU145 prostate cancer cells to cisplatin
- Integrated bulk and single-cell transcriptomic analyses with experimental validation identify PLOD1 as a diagnostic biomarker and TGF-β1-responsive profibrotic mediator in dupuytren’s disease
BibTeX
@article{cengiz2026ceranib2,
title = {{Ceranib-2 potentiates cisplatin activity under an experimental in vitro hipec-like model by inducing integrated stress and cell death pathways in ovarian cancer}},
author = {Celal Cengiz and Canan Vejselova Sezer and Bahri Gür and Hatice Mehtap Kutlu and Mustafa Cengiz},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-74581-6},
url = {https://www.nature.com/articles/s41598-026-74581-6},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ceranib-2 potentiates cisplatin activity under an experimental in vitro hipec-like model by inducing integrated stress and cell death pathways in ovarian cancer
AU - Celal Cengiz
AU - Canan Vejselova Sezer
AU - Bahri Gür
AU - Hatice Mehtap Kutlu
AU - Mustafa Cengiz
PY - 2026
DA - 2026/10/06
JO - Scientific Reports
DO - 10.1038/s41598-026-74581-6
UR - https://www.nature.com/articles/s41598-026-74581-6
AB - This study aims to investigate whether the addition of Ceranib-2, an acid ceramidase inhibitor, could enhance the cytotoxic efficacy of cisplatin under hyperthermic conditions using an OVCAR-3 ovarian cancer cell model. The combination of cisplatin and ceranib-2, administered at a tolerable hyperthermic temperature of 39 ˚C, significantly decreased cell viability and induced robust programmed cell death compared to monotherapies. Notably, our findings reveal a complex mechanistic interplay: while cisplatin monotherapy primarily relied on ROS-dependent pathways, the combination treatment triggered potent anticancer effects through ceramide-driven ER stress and autophagy, even exhibiting lower ROS levels than cisplatin alone. This suggests a shift toward ROS-independent death mechanisms. Furthermore, we observed a significant 4-fold upregulation of the anti-apoptotic protein Bcl-2 in the combination group. This increase is characterized as a compensatory pro-survival response to intense cellular stress, which was ultimately overwhelmed by the marked activation of caspase-3/7 and mitochondrial depolarization. The integration of in vitro GDH activity measurements and in silico molecular docking analyses suggests that ceranib-2 may interact with glutamate dehydrogenase (GDH), potentially contributing to the observed reduction in GDH activity. The docking results further indicate a possible interaction with the NAD⁺-binding domain and C-terminal α-helix, supporting a putative allosteric binding mode that warrants further experimental validation. Additionally, the combination treatment significantly impaired the colony-forming ability and spread of tumor cells. These results demonstrate that the cisplatin and ceranib-2 combination elicit a synergistic effect by utilizing complementary pathways to overcome chemoresistance. Consequently, this study provides valuable insights and experimental evidence for future optimization of HIPEC protocols by targeting ceramide metabolism and ER stress signaling to improve therapeutic outcomes in ovarian cancer.
SN - 2045-2322
ER -